Omics Tools and MDx Stocks Sluggish in April; More than Half of Companies See Share Prices Drop | GenomeWeb

NEW YORK (GenomeWeb News) – More than half of the companies operating in the omics tools and molecular diagnostics space saw their stock prices drop in April, resulting in a sluggish GenomeWeb Daily News Index for the month.

Of the 29 firms in the GWDN Index, 16 declined during the past month, and overall the index inched up less than 1 percent. It trailed the Dow Jones Industrial Average and the Nasdaq, which grew a little less than 2 percent each, as well as the Nasdaq Biotech Index, which gained almost 8 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.